Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials

Kavirajan, Harish, Schneider, Lon S · 2007 · The Lancet Neurology

Abstract

Background Cholinesterase inhibitors and memantine do not have regulatory approval in most of the world for treatment of vascular dementia. A systematic review and meta-analysis was undertaken to assess the evidence for efficacy and safety of cholinesterase inhibitors and memantine in vascular dementia.Methods PubMed, BIOSIS, International Pharmaceutical Abstracts, and Cochrane registries were searched for randomised, placebo-controlled trials on cholinesterase inhibitors and memantine in patients with vascular dementia. Trial methods, clinical characteristics, outcomes, and adverse events were extracted and checked. Meta-analytic methods using fixed-effects models were used to give summaries of each drug's effects.Findings Three donepezil, two galantamine, one rivastigmine, and two memantine trials, comprising 3093 patients on the study drugs and 2090 patients on placebo, met the selection criteria. Trials were of 6-month duration with similar vascular dementia criteria and outcome measures. Cognitive effects on the Alzheimer's Disease Assessment scale were significant for all drugs, ranging from a -1.10 point mean difference (95% CI -2.15 to -0.05) for rivastigmine to -2.17 for 10 mg daily donepezil (95% CI -2.98 to -1.35). Only 5 mg daily donepezil had an effect on the Clinicians' Global Impression of Change scale (odds ratio 1.51 [95% CI 1.11-2.07]). No behavioural or functional benefits were observed, except for a -0.95 point difference (95% CI -1.74 to -0.16) with 10 mg daily donepezil on the Alzheimer's Disease Functional Assessment and Change Scale. Compared with placebo, more dropouts and adverse events (anorexia, nausea, vomiting, diarrhoea, and insomnia) occurred with the cholinesterase inhibitors, but not with memantine.Interpretation Cholinesterase inhibitors and memantine produce small benefits in cognition of uncertain clinical significance in patients with mild to moderate vascular dementia. Data are insufficient to support widespread use of these drugs in vascular dementia. Individual patient analyses are needed to identify subgroups of patients with vascular dementia who might benefit.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(07)70195-3

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 37 references

Research works printed but not linked: 3

  1. Auchus AP, Brashear HR, Salloway S, et al. Results of a trial of galantamine in subjects with vascular dementia confirmed by central MRI reading. Proceedings of the 56th Annual Meeting of the American Academy of Neurology (AAN), San Francisco, CA, USA; April 24–May 1, 2004; LBS009.
  2. Passmore AP, Pratt RD, Perdomo CA. A comparison of the cognitive benefits of donepezil in patients with cortical and subcortical vascular dementia: a subanalysis of two 24-week, randomized, double-blind, placebo-controlled trials. Proceedings of the Third International Conference on Vascular Dementia, Prague, Czech Republic; Oct 23–26, 2003; 33.00.
  3. Scheltens, 2005, Effect of galantamine on cognition in subgroups of patients with vascular dementia, Int Psychogeriatr, 17, 318

Cited by

See all 503

Metadata

Authors
Kavirajan, H., & Schneider, L. S.
Affiliations
  • University of California, Los Angeles (US)
  • University of Southern California (US)
Corresponding author
Kavirajan, Harish
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2007-09
Volume
6
Issue
9
Pages
782-792
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2166039854
Cited by
497
References
37
Citations by year
2026: 15 · 2025: 17 · 2024: 22 · 2023: 18 · 2022: 25 · 2021: 45 · 2020: 29 · 2019: 30 · 2018: 30 · 2017: 25 · 2016: 27 · 2015: 22 · 2014: 30 · 2013: 29 · 2012: 18
FWCI
3.84
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute on Aging (AG 05142, P50AG005142)
  • Janssen Pharmaceuticals
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
vascular dementia, cholinesterase inhibitors, memantine, donepezil, galantamine, rivastigmine, cognitive function, Alzheimer's Disease Assessment Scale, adverse events, drug efficacy, dementia treatment
MeSH terms
Rivastigmine, Donepezil, Cholinesterase Inhibitors, Dose-Response Relationship, Drug, Double-Blind Method, Drug Evaluation, Galantamine, Humans, Indans, Memantine, Piperidines, Time Factors, Dementia, Vascular, Odds Ratio, Randomized Controlled Trials as Topic, Databases, Bibliographic, Treatment Outcome, Excitatory Amino Acid Antagonists, Phenylcarbamates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. https://app.cochat.ai/papers/10.1016/s1474-4422(07)70195-3
The paper
Kavirajan, H., & Schneider, L. S. (2007). Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(07)70195-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.